{"url":"https://newsforagent.com/news/2026-11-01/johnson-johnson-impella-hrpci-mortality","markdown_url":"https://newsforagent.com/news/2026-11-01/johnson-johnson-impella-hrpci-mortality.md","title":"Johnson & Johnson Impella Data Show Lower Mortality in HRPCI","headline":"Johnson & Johnson Reports Lower Mortality for Impella-Supported HRPCI Versus CHIP-BCIS3","description":"Johnson & Johnson reported three analyses of 1,379 real-world Impella HRPCI patients showing lower in-hospital and 30- and 90-day mortality than CHIP-BCIS3.","section":"Research & Clinical Trials","published_at":"2026-11-01T13:13:59+00:00","modified_at":"2026-11-01T13:13:59+00:00","author":"News Desk","key_takeaways":["Johnson & Johnson reported three analyses covering 1,379 Impella-supported HRPCI patients in U.S. and EU real-world data.","The analyses showed lower in-hospital, 30-day and 90-day mortality versus CHIP-BCIS3.","The PROTECT IV randomized controlled trial readout is anticipated in 2027."],"companies":[{"name":"Johnson & Johnson Services, Inc.","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc","website":"https://www.jnj.com"}],"source":{"publisher":"TradingView","title":"Johnson & Johnson (JNJ) Reports Positive Real-World Impella HRPCI Outcomes vs CHIP-BCIS3","url":"https://www.tradingview.com/news/tradingview:2760a2836f323:0-johnson-johnson-jnj-reports-positive-real-world-impella-hrpci-outcomes-vs-chip-bcis3/"},"other_sources":[],"tags":["Research & Clinical Trials","Johnson & Johnson Services, Inc."],"body_markdown":"[Johnson](https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc) & Johnson reported three analyses showing lower in-hospital and 30- and 90-day mortality for patients who received Impella-supported high-risk PCI in real-world U.S. and EU data compared with CHIP-BCIS3, covering 1,379 patients. [TradingView](https://www.tradingview.com/news/tradingview:2760a2836f323:0-johnson-johnson-jnj-reports-positive-real-world-impella-hrpci-outcomes-vs-chip-bcis3/) carried the report on November 1, 2026.\n\n## What the Three Impella Analyses Found\n\nJohnson & Johnson said the analyses compared Impella-supported high-risk percutaneous coronary intervention patients in real-world U.S. and EU data against CHIP-BCIS3. The company reported lower in-hospital cardiovascular mortality for the Impella-supported group. It also reported lower mortality at 30 days and at 90 days after the procedure.\n\nThe analyses covered 1,379 HRPCI patients. Johnson & Johnson noted support duration as a factor in the outcomes. The company said the PROTECT IV randomized controlled trial readout is anticipated in 2027.\n\nJohnson & Johnson is the New Brunswick-based pharmaceutical and medical technology group led by chairman and chief executive officer Joaquin Duato, according to [company records](https://akta.pro/company-data). Its MedTech segment includes the Impella heart pump line.\n\n## Johnson & Johnson's Scale Behind the Impella Program\n\nJohnson & Johnson raised its 2026 sales guidance to a $100.8 billion midpoint after reporting 9.9% first-quarter sales growth to $24.1 billion, according to akta.pro company records. The company reported $94.2 billion in revenue for 2025 with 6% growth and net income of $26.8 billion. The same records list a $1.5 million grant in August 2026 led by the North Carolina Department of Commerce.\n\n## Earlier Johnson & Johnson Trial Results\n\nOn October 24, 2026, Johnson & Johnson announced PROTEUS substudy results showing apalutamide plus androgen deprivation therapy before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer, PR Newswire reported. The same day, Yahoo reported that the company said its experimental prostate cancer drug caused tumors to shrink or disappear in an early-stage trial, with PSA levels falling by at least 50% in 77% of 31 evaluable patients.\n\nOn October 29, 2026, Seeking Alpha reported that Johnson & Johnson posted third-quarter revenue of $25.4 billion, up 5.9%, and raised its 2026 adjusted EPS forecast to $11.10.\n\n## Johnson & Johnson's December 8 Review\n\nJohnson & Johnson will host an Enterprise Business Review for the investment community on December 8, 2026, with presentations from company leaders on Innovative Medicine and MedTech, Stock Titan reported.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}